

Mina Nikanjam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/982311/publications.pdf>

Version: 2024-02-01

27
papers

967
citations

687220

13
h-index

610775

24
g-index

27
all docs

27
docs citations

27
times ranked

1526
citing authors

#	ARTICLE	IF	CITATIONS
1	Cetuximab in Patients with Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Alterations.. , 2022, 5, .		0
2	Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients. <i>Molecular Oncology</i> , 2021, 15, 67-79.	2.1	28
3	Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 184-192.	2.3	6
4	S-warfarin limited sampling strategy with a population pharmacokinetic approach to estimate exposure and cytochrome P450 (CYP) 2C9 activity in healthy adults. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1349-1356.	0.8	1
5	<i>BRAF</i> V600E/V600K Mutations versus Nonstandard Alterations: Prognostic Implications and Therapeutic Outcomes. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1072-1079.	1.9	6
6	Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study. <i>Genome Medicine</i> , 2021, 13, 155.	3.6	44
7	Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients. <i>International Journal of Cancer</i> , 2020, 146, 3087-3097.	2.3	20
8	Targeting fusions for improved outcomes in oncology treatment. <i>Cancer</i> , 2020, 126, 1315-1321.	2.0	14
9	Development and preclinical pharmacology of a novel dCK inhibitor, DI-87. <i>Biochemical Pharmacology</i> , 2020, 172, 113742.	2.0	8
10	Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. <i>Nature Communications</i> , 2020, 11, 4965.	5.8	172
11	Tumor mutational burden is not predictive of cytotoxic chemotherapy response. <i>Oncolmmunology</i> , 2020, 9, 1781997.	2.1	8
12	Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. <i>Oncolmmunology</i> , 2020, 9, 1708065.	2.1	41
13	Review of precision cancer medicine: Evolution of the treatment paradigm. <i>Cancer Treatment Reviews</i> , 2020, 86, 102019.	3.4	327
14	Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds. <i>Oncolmmunology</i> , 2020, 9, 1710052.	2.1	17
15	Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients. <i>EJNMMI Research</i> , 2020, 10, 150.	1.1	9
16	Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy. <i>Cureus</i> , 2020, 12, e8967.	0.2	2
17	Population pharmacokinetics of siltuximab: impact of disease state. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 993-1001.	1.1	6
18	Population pharmacokinetic analysis of high-dose methotrexate in pediatric and adult oncology patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 1339-1348.	1.1	33

#	ARTICLE	IF	CITATIONS
19	Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 171-178.	1.1	21
20	New Rationales and Designs for Clinical Trials in the Era of Precision Medicine. , 2018, , 30-30.		0
21	Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 1604-1617.	1.0	11
22	Dosing Oncology Therapeutics in Combination Therapy for Renal Dysfunction: The University of California San Diego Study of Personalized Cancer Therapy to Determine Response and Toxicity (UCSD-PREDICT) Experience. <i>Cureus</i> , 2018, 10, e3634.	0.2	0
23	Dosing Three-Drug Combinations That Include Targeted Anti-Cancer Agents: Analysis of 37,763 Patients. <i>Oncologist</i> , 2017, 22, 576-584.	1.9	39
24	ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways. <i>Nature Communications</i> , 2017, 8, 241.	5.8	44
25	Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns. <i>Oncolmmunology</i> , 2017, 6, e1338997.	2.1	29
26	Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013. <i>International Journal of Cancer</i> , 2016, 139, 2135-2141.	2.3	31
27	Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers. <i>Oncotarget</i> , 2016, 7, 11310-11320.	0.8	50